Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Capital Expenditures (2016 - 2025)

Adma Biologics (ADMA) has disclosed Capital Expenditures for 13 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 60.68% year-over-year to $1.1 million, compared with a TTM value of $22.6 million through Dec 2025, up 174.43%, and an annual FY2025 reading of $22.6 million, up 174.43% over the prior year.
  • Capital Expenditures was $1.1 million for Q4 2025 at Adma Biologics, down from $14.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $14.4 million in Q3 2025 and bottomed at $757000.0 in Q3 2023.
  • Average Capital Expenditures over 5 years is $3.1 million, with a median of $2.7 million recorded in 2021.
  • The sharpest move saw Capital Expenditures crashed 77.87% in 2023, then soared 1260.61% in 2025.
  • Year by year, Capital Expenditures stood at $3.7 million in 2021, then rose by 1.98% to $3.7 million in 2022, then crashed by 68.07% to $1.2 million in 2023, then surged by 130.33% to $2.8 million in 2024, then crashed by 60.68% to $1.1 million in 2025.
  • Business Quant data shows Capital Expenditures for ADMA at $1.1 million in Q4 2025, $14.4 million in Q3 2025, and $2.4 million in Q2 2025.